First-in-human (FIH) oncology trials present some of the most complex scientific, regulatory, and operational challenges in clinical development.
As sponsors transition from preclinical promise to first patient dosing, success depends on rigorous regulatory preparation, risk-based execution, and a genuinely patient-centric trial design. The focus is shifting from purely protocol-driven execution to a strategic, end-to-end approach that de-risks early development while safeguarding patient safety and data integrity.
Read our guide to explore more about:
- How to strengthen regulatory readiness and IND strategies for FIH oncology trials
- How to manage complex cohort design and dose escalation with confidence
- How to accelerate site activation and early-phase trial startup
- How patient-centric trial design improves recruitment, retention, and data quality